Bioluminescent reporters for rapid mechanism of action assessment in tuberculosis drug discovery

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 11, 2016, Pages 6748-6757

  Naran, Krupa ^a   Moosa, Atica ^a   Barry, Clifton E ^a,b   Boshoff, Helena I M ^b   Mizrahi, Valerie ^a   Warner, Digby F ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIAL PROTEIN; INIBAC PROTEIN; LUXCDABE PROTEIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; LUCIFERASE; RADA PROTEIN, BACTERIA; RECA PROTEIN;

ARTICLE; ASSAY; BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIOLUMINESCENCE; BIOLUMINESCENCE REPORTER ASSAY; BIOSYNTHESIS; DRUG MECHANISM; DRUG TARGETING; INCUBATION TIME; INIBAC GENE; LUXCDABE GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPERON; PHOTORHABDUS LUMINESCENS; PRIORITY JOURNAL; PROMOTER REGION; TUBERCULOSIS; CELL WALL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIGH THROUGHPUT SCREENING; LUMINESCENCE; METABOLISM; PHOTORHABDUS; REPORTER GENE;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CELL WALL; DNA, BACTERIAL; DNA-BINDING PROTEINS; DRUG DISCOVERY; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MYCOBACTERIUM TUBERCULOSIS; OPERON; PHOTORHABDUS; PROMOTER REGIONS, GENETIC; REC A RECOMBINASES;

EID: 84995467570     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01178-16     Document Type: Article

References (53)

1. Coxon GD, Cooper CB, Gillespie SH, McHugh TD. 2012. Strategies and challenges involved in the discovery of new chemical entities during earlystage tuberculosis drug discovery. J Infect Dis 205(Suppl 2):S258-264. http://dx.doi.org/10.1093/infdis/jis191.
2. Mdluli K, Kaneko T, Upton A. 2014. Tuberculosis drug discovery and emerging targets. Ann N Y Acad Sci 1323:56-75. http://dx.doi.org/10.1111/nyas.12459.
3. Hoagland DT, Liu J, Lee RB, Lee RE. 2016. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev 102:55-72. http://dx.doi.org/10.1016/j.addr.2016.04.026.
4. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T. 2010. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1:57. http://dx.doi.org/10.1038/ncomms1060.
5. Goldman RC. 2013. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis (Edinb) 93:569-588. http://dx.doi.org/10.1016/j.tube.2013.09.003.
6. Early JV, Casey A, Martinez-Grau MA, Valcarcel IC, Vieth M, Ollinger J, Bailey MA, Alling T, Files M, Ovechkina Y, Parish T. 2016. Oxadiazoles have butyrate-specific conditional activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 60:3608-3616. http://dx.doi.org/10.1128/AAC.02896-15.
7. Gold B, Smith R, Nguyen Q, Roberts J, Ling Y, Lopez Quezeda L, Somersan-Karakaya S, Warrier T, Little D, Pingle M, Zhang D, Ballinger E, Zimmerman M, Dartois V, Hanson PR, Mitscher LA, Porubsky P, Rogers S, Schoenen FJ, Nathan CF, Aube J. 2016. Novel cephalosporins selectively activeonnon-replicating Mycobacterium tuberculosis. JMedChem59:6027-6044. http://dx.doi.org/10.1021/acs.jmedchem.5b01833.
8. Grant SS, Kawate T, Nag PP, Silvis MR, Gordon K, Stanley SA, Kazyanskaya E, Nietupski R, Golas A, Fitzgerald M, Cho S, Franzblau SG, Hung DT. 2013. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem Biol 8:2224-2234. http://dx.doi.org/10.1021/cb4004817.
9. Arora K, Ochoa-Montano B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LA, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE, III, Boshoff HI. 2014. Respiratory flexibility in response to inhibition of cytochrome c oxidase in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:6962-6965. http://dx.doi.org/10.1128/AAC.03486-14.
10. van der Westhuyzen R, Winks S, Wilson CR, Boyle GA, Gessner RK, Soares de Melo C, Taylor D, de Kock C, Njoroge M, Brunschwig C, Lawrence N, Rao SP, Sirgel F, van Helden P, Seldon R, Moosa A, Warner DF, Arista L, Manjunatha UH, Smith PW, Street LJ, Chibale K. 2015. Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: a novel antimycobacterial class targeting mycobacterial respiration. J Med Chem 58:9371-9381. http://dx.doi.org/10.1021/acs.jmedchem.5b01542.
11. Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8:e75245. http://dx.doi.org/10.1371/journal.pone.0075245.
12. Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, Daniels L, Dick T, Pang SS, Barry CE. 2006. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103:431-436. http://dx.doi.org/10.1073/pnas.0508392103.
13. Li W, Upadhyay A, Fontes FL, North EJ, Wang Y, Crans DC, Grzegorzewicz AE, Jones V, Franzblau SG, Lee RE, Crick DC, Jackson M. 2014. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:6413-6423. http://dx.doi.org/10.1128/AAC.03229-14.
14. Murima P, de Sessions PF, Lim V, Naim AN, Bifani P, Boshoff HI, Sambandamurthy VK, Dick T, Hibberd ML, Schreiber M, Rao SP. 2013. Exploring the mode of action of bioactive compounds by microfluidic transcriptional profiling in mycobacteria. PLoS One 8:e69191. http://dx.doi.org/10.1371/journal.pone.0069191.
15. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism novel insights into drug mechanisms of action. J Biol Chem 279:40174-40184. http://dx.doi.org/10.1074/jbc.M406796200.
16. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. 2012. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother 56: 5782-5789. http://dx.doi.org/10.1128/AAC.01125-12.
17. Alland D, Steyn AJ, Weisbrod T, Aldrich K, Jacobs WR. 2000. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J Bacteriol 182:1802-1811. http://dx.doi.org/10.1128/JB.182.7.1802-1811.2000.
18. Fischer HP, Brunner NA, Wieland B, Paquette J, Macko L, Ziegelbauer K, Freiberg C. 2004. Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery. Genome Res 14:90-98.
19. Gupta N, Singh B. 2008. Deciphering kas operon locus in Mycobacterium aurum and genesis of a recombinant strain for rational-based drug screening. J Appl Microbiol 105:1703-1710. http://dx.doi.org/10.1111/j.1365 -2672.2008.03888.x.
20. Sun D, Cohen S, Mani N, Murphy C, Rothstein DM. 2002. A pathwayspecific cell based screening system to detect bacterial cell wall inhibitors. J Antibiot (Tokyo) 55:279-287. http://dx.doi.org/10.7164/antibiotics.55 .279.
21. Balganesh TS, Alzari PM, Cole ST. 2008. Rising standards for tuberculosis drug development. Trends Pharmacol Sci 29:576-581. http://dx.doi.org/10.1016/j.tips.2008.08.001.
22. Fan J, de Jonge BL, MacCormack K, Sriram S, McLaughlin RE, Plant H, Preston M, Fleming PR, Albert R, Foulk M. 2014. A novel highthroughput cell-based assay aimed at identifying inhibitors of DNA metabolism in bacteria. Antimicrob Agents Chemother 58:7264-7272. http://dx.doi.org/10.1128/AAC.03475-14.
23. Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. 2012. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 67:404-414. http://dx.doi.org/10.1093/jac/dkr472.
24. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD. 2010. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5:e10777. http://dx.doi.org/10.1371/journal.pone.0010777.
25. Sharma S, Gelman E, Narayan C, Bhattacharjee D, Achar V, Humnabadkar V, Balasubramanian V, Ramachandran V, Dhar N, Dinesh N. 2014. Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:5801-5808. http://dx.doi.org/10.1128/AAC.03205-14.
26. Zhang T, Li SY, Nuermberger EL. 2012. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, noninvasive assessment of drug and vaccine efficacy. PLoS One 7:e29774. http://dx.doi.org/10.1371/journal .pone.0029774.
27. Vocat A, Hartkoorn RC, Lechartier B, Zhang M, Dhar N, Cole ST, Sala C. 2015. Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:4012-4019. http://dx.doi.org/10.1128/AAC.00528-15.
28. Mitchison D, Davies G. 2012. The chemotherapy of tuberculosis: past, present, and future. Int J Tuberc Lung Dis 16:724-732. http://dx.doi.org/10.5588/ijtld.12.0083.
29. Alland D, Kramnik I, Weisbrod TR, Otsubo L, Cerny R, Miller LP, Jacobs WR, Jr, Bloom BR. 1998. Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 95:13227-13232. http://dx.doi.org/10.1073/pnas.95.22.13227.
30. Boshoff HI, Reed MB, Barry CE, Mizrahi V. 2003. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 113:183-193. http://dx.doi.org/10.1016/S0092-8674(03)00270-8.
31. Smollett KL, Smith KM, Kahramanoglou C, Arnvig KB, Buxton RS, Davis EO. 2012. Global analysis of the regulon of the transcriptional repressor LexA, a key component of SOS response in Mycobacterium tuberculosis. J Biol Chem 287:22004-22014. http://dx.doi.org/10.1074/jbc .M112.357715.
32. Gamulin V, Cetkovic H, Ahel I. 2004. Identification of a promoter motif regulating the major DNA damage response mechanism of Mycobacterium tuberculosis. FEMS Microbiol Lett 238:57-63. http://dx.doi.org/10.1111/j.1574-6968.2004.tb09737.x.
33. Baker WR, Shaopei C, Keeler EL. September 1997. Nitroimidazole antibacterial compounds and methods of use thereof. US patent 5668127 A.
34. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE, III. 2003. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 5:172-187. http://dx.doi.org/10.1021/cc020071p.
35. Lee MH, Pascopella L, Jacobs WR, Jr, Hatfull GF. 1991. Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc Natl Acad Sci U S A 88:3111-3115. http://dx.doi.org/10.1073/pnas.88.8.3111.
36. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, Jacobs WR, Jr, Mizrahi V, Parish T, Rubin E, Sassetti C, Sacchettini JC. 2010. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 192:3645-3653. http://dx.doi.org/10.1128/JB.00166-10.
37. Collins L, Franzblau SG. 1997. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41:1004-1009.
38. Collins L, Torrero M, Franzblau S. 1998. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 344-347.
39. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA. 2005. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56:968-974. http://dx.doi.org/10.1093/jac/dki319.
40. Feng X, Zhu W, Schurig-Briccio LA, Lindert S, Shoen C, Hitchings R, Li J, Wang Y, Baig N, Zhou T, Kim BK, Crick DC, Cynamon M, McCammon JA, Gennis RB, Oldfield E. 2015. Anti-infectives targeting enzymes and the proton motive force. Proc Natl Acad Sci U S A 112: E7073-E7082. http://dx.doi.org/10.1073/pnas.1521988112.
41. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu YL, Molohon K, Orlean P, Mitchell DA, Freitas-Junior L, Ren F, Sun H, Jiang T, Li Y, Guo RT, Cole ST, Gennis RB, Crick DC, Oldfield E. 2014. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 57:3126-3139. http://dx.doi.org/10.1021/jm500131s.
42. Manjunatha U, Boshoff HI, Barry CE. 2009. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2:215-218. http://dx.doi.org/10.4161/cib.2.3.7926.
43. Tomasz M. 1995. Mitomycin C: small, fast, and deadly (but very selective). Chem Biol 2:575-579. http://dx.doi.org/10.1016/1074-5521(95)90120-5.
44. Rastogi N, Labrousse V, Goh KS. 1996. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 33:167-175. http://dx.doi.org/10.1007/s002849900095.
45. Jarosz DF, Godoy VG, Delaney JC, Essigmann JM, Walker GC. 2006. A single amino acid governs enhanced activity of DinB DNA polymerases on damaged templates. Nature 439:225-228. http://dx.doi.org/10.1038/nature04318.
46. Singh V, Brecik M, Mukherjee R, Evans JC, Svetlíková Z, Blaško J, Surade S, Blackburn J, Warner DF, Mikušová K. 2015. The complex mechanism of antimycobacterial action of 5-fluorouracil. Chem Biol 22: 63-75. http://dx.doi.org/10.1016/j.chembiol.2014.11.006.
47. Dartois V, Barry CE, III. 2013. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 23:4741-4750. http://dx.doi.org/10.1016/j.bmcl.2013.07.006.
48. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE, III, Dartois V. 2015. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 21:1223-1227. http://dx.doi.org/10.1038/nm .3937.
49. Dwyer DJ, Collins JJ, Walker GC. 2015. Unraveling the physiological complexities of antibiotic lethality. Annu Rev Pharmacol Toxicol 55:313-332. http://dx.doi.org/10.1146/annurev-pharmtox-010814-124712.
50. Belenky P, Ye JD, Porter CB, Cohen NR, Lobritz MA, Ferrante T, Jain S, Korry BJ, Schwarz EG, Walker GC, Collins JJ. 2015. Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage. Cell Rep 13:968-980. http://dx.doi.org/10.1016/j.celrep.2015.09.059.
51. Lobritz MA, Belenky P, Porter CB, Gutierrez A, Yang JH, Schwarz EG, Dwyer DJ, Khalil AS, Collins JJ. 2015. Antibiotic efficacy is linked to bacterial cellular respiration. Proc Natl Acad Sci U S A 112:8173-8180. http://dx.doi.org/10.1073/pnas.1509743112.
52. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. 2011. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 286:10276-10287. http://dx.doi.org/10.1074/jbc.M110.200501.
53. Saini V, Cumming BM, Guidry L, Lamprecht DA, Adamson JH, Reddy VP, Chinta KC, Mazorodze JH, Glasgow JN, Richard-Greenblatt M, Gomez-Velasco A, Bach H, Av-Gay Y, Eoh H, Rhee K, Steyn AJ. 2016. Ergothioneine maintains redox and bioenergetic homeostasis essential for drug susceptibility and virulence of Mycobacterium tuberculosis. Cell Rep 14:572-585. http://dx.doi.org/10.1016/j.celrep.2015.12.056.